Oncologic theranostics: recognition of this concept in antigen-directed cancer therapy for colorectal cancer with anti-TAG-72 monoclonal antibodies

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

Stephen P Povoski is currently associated with Enlyton, Ltd. as a non-salaried staff scientist, and has stock ownership in Enlyton, Ltd. Ioannis S Hatzaras has no potential financial or competing interests. Cathy M Mojzisik is currently associated with Enlyton, Ltd. as a non-salaried staff scientist, has stock ownership in Enlyton, Ltd., has stock ownership in Neoprobe Corporation, is currently employed by Veeda Oncology, and has previously been employed by and received consultant fees/honorariums from Neoprobe Corporation. Edward W Martin Jr is currently associated with Enlyton, Ltd. as the non-salaried Chief Science Officer, has stock ownership in Enlyton, Ltd., has stock ownership in Neoprobe Corporation, has previously received research support and consultant fees/honorariums from Neoprobe Corporation, and was an original founding member of Neoprobe Corporation in 1983. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.